SPOTLIGHT -
What’s Next With Next-Generation BRAF Inhibitors?
Targeted therapy for patients with activating BRAF mutations has demonstrated the potential for personalized medicine in patients with metastatic melanoma. Initial study results were promising and dramatic.
